Fierce Biotech News & Reports
6 天之前 · Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on Fierce Biotech as their must-read source for the latest news, analysis and data in the world of biotech ...
Biotech | Fierce Biotech
6 天之前 · As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team and let us know.
Fierce Biotech Fundraising Tracker 2024
3 天之前 · A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...
MedTech | Fierce Biotech
5 天之前 · Version 2 of the TruSight Oncology 500 research-use-only assay is currently under development, the company said, with its release set for mid-2025.
Pharma - Fierce Biotech
4 天之前 · While one might expect a positive readout from a biotech’s lead asset to boost stock prices, Pyxis Oncology’s shares tell a different story.
Research - Fierce Biotech
2024年11月14日 · Howard Chang, M.D., Ph.D., is stepping into the CSO role that Jay Bradner, M.D., previously occupied.
Cell & Gene Therapy - Fierce Biotech
Explore news and insight around cell and gene therapy, including new technology and information in this evolving biotech field. Read on to understand how the industry is addressing gene …
Introducing Fierce Biotech's 2024 Fierce 15
2024年8月5日 · One of our Fierce 15 honorees dove deep into the ocean for inspiration from the sea squirt to develop new human therapeutics. Another thought the adorable 13-lined ground squirrel, with its polka ...
A cell therapy reckoning - Fierce Biotech
2024年5月31日 · The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events
Venture Capital - Fierce Biotech
5 天之前 · Versant has unveiled Pep2Tango, a biotech developing next-gen obesity therapeutics with multiple targets to overcome GLP-1 limitations.